Last reviewed · How we verify
NILOTINIB HYDROCHLORIDE MONOHYDRATE
NILOTINIB HYDROCHLORIDE MONOHYDRATE is a drug. It is currently FDA-approved (first approved 2007).
At a glance
| Generic name | NILOTINIB HYDROCHLORIDE MONOHYDRATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2007 |
Approved indications
Common side effects
Key clinical trials
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial (PHASE2)
- Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia (PHASE2)
- Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NILOTINIB HYDROCHLORIDE MONOHYDRATE CI brief — competitive landscape report
- NILOTINIB HYDROCHLORIDE MONOHYDRATE updates RSS · CI watch RSS
Frequently asked questions about NILOTINIB HYDROCHLORIDE MONOHYDRATE
What is NILOTINIB HYDROCHLORIDE MONOHYDRATE?
NILOTINIB HYDROCHLORIDE MONOHYDRATE is a Small molecule drug.
When was NILOTINIB HYDROCHLORIDE MONOHYDRATE approved?
NILOTINIB HYDROCHLORIDE MONOHYDRATE was first approved on 2007.
What development phase is NILOTINIB HYDROCHLORIDE MONOHYDRATE in?
NILOTINIB HYDROCHLORIDE MONOHYDRATE is FDA-approved (marketed).